These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 20307063)

  • 1. Discovery of novel 6,6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists.
    Blum CA; Caldwell T; Zheng X; Bakthavatchalam R; Capitosti S; Brielmann H; De Lombaert S; Kershaw MT; Matson D; Krause JE; Cortright D; Crandall M; Martin WJ; Murphy BA; Boyce S; Jones AB; Mason G; Rycroft W; Perrett H; Conley R; Burnaby-Davies N; Chenard BL; Hodgetts KJ
    J Med Chem; 2010 Apr; 53(8):3330-48. PubMed ID: 20307063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrido[2,3-b]pyrazines, discovery of TRPV1 antagonists with reduced potential for the formation of reactive metabolites.
    Hodgetts KJ; Blum CA; Caldwell T; Bakthavatchalam R; Zheng X; Capitosti S; Krause JE; Cortright D; Crandall M; Murphy BA; Boyce S; Brian Jones A; Chenard BL
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4359-63. PubMed ID: 20615696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel vanilloid receptor-1 antagonists: 1. Conformationally restricted analogues of trans-cinnamides.
    Norman MH; Zhu J; Fotsch C; Bo Y; Chen N; Chakrabarti P; Doherty EM; Gavva NR; Nishimura N; Nixey T; Ognyanov VI; Rzasa RM; Stec M; Surapaneni S; Tamir R; Viswanadhan VN; Treanor JJ
    J Med Chem; 2007 Jul; 50(15):3497-514. PubMed ID: 17585749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazoles.
    Ognyanov VI; Balan C; Bannon AW; Bo Y; Dominguez C; Fotsch C; Gore VK; Klionsky L; Ma VV; Qian YX; Tamir R; Wang X; Xi N; Xu S; Zhu D; Gavva NR; Treanor JJ; Norman MH
    J Med Chem; 2006 Jun; 49(12):3719-42. PubMed ID: 16759115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential involvement of TRPV1 receptors at the central and peripheral nerves in CFA-induced mechanical and thermal hyperalgesia.
    Kanai Y; Hara T; Imai A; Sakakibara A
    J Pharm Pharmacol; 2007 May; 59(5):733-8. PubMed ID: 17524240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate.
    Doherty EM; Fotsch C; Bannon AW; Bo Y; Chen N; Dominguez C; Falsey J; Gavva NR; Katon J; Nixey T; Ognyanov VI; Pettus L; Rzasa RM; Stec M; Surapaneni S; Tamir R; Zhu J; Treanor JJ; Norman MH
    J Med Chem; 2007 Jul; 50(15):3515-27. PubMed ID: 17585750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade.
    Gavva NR; Bannon AW; Hovland DN; Lehto SG; Klionsky L; Surapaneni S; Immke DC; Henley C; Arik L; Bak A; Davis J; Ernst N; Hever G; Kuang R; Shi L; Tamir R; Wang J; Wang W; Zajic G; Zhu D; Norman MH; Louis JC; Magal E; Treanor JJ
    J Pharmacol Exp Ther; 2007 Oct; 323(1):128-37. PubMed ID: 17652633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and characterization of a noncompetitive antagonist of the transient receptor potential vanilloid subunit 1 channel with in vivo analgesic and anti-inflammatory activity.
    García-Martínez C; Fernández-Carvajal A; Valenzuela B; Gomis A; Van Den Nest W; Ferroni S; Carreño C; Belmonte C; Ferrer-Montiel A
    J Pain; 2006 Oct; 7(10):735-46. PubMed ID: 17018334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties.
    Gomtsyan A; Bayburt EK; Schmidt RG; Zheng GZ; Perner RJ; Didomenico S; Koenig JR; Turner S; Jinkerson T; Drizin I; Hannick SM; Macri BS; McDonald HA; Honore P; Wismer CT; Marsh KC; Wetter J; Stewart KD; Oie T; Jarvis MF; Surowy CS; Faltynek CR; Lee CH
    J Med Chem; 2005 Feb; 48(3):744-52. PubMed ID: 15689158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management.
    Gomtsyan A; Bayburt EK; Schmidt RG; Surowy CS; Honore P; Marsh KC; Hannick SM; McDonald HA; Wetter JM; Sullivan JP; Jarvis MF; Faltynek CR; Lee CH
    J Med Chem; 2008 Feb; 51(3):392-5. PubMed ID: 18183945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties.
    Wang HL; Katon J; Balan C; Bannon AW; Bernard C; Doherty EM; Dominguez C; Gavva NR; Gore V; Ma V; Nishimura N; Surapaneni S; Tang P; Tamir R; Thiel O; Treanor JJ; Norman MH
    J Med Chem; 2007 Jul; 50(15):3528-39. PubMed ID: 17585751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats.
    Lehto SG; Tamir R; Deng H; Klionsky L; Kuang R; Le A; Lee D; Louis JC; Magal E; Manning BH; Rubino J; Surapaneni S; Tamayo N; Wang T; Wang J; Wang J; Wang W; Youngblood B; Zhang M; Zhu D; Norman MH; Gavva NR
    J Pharmacol Exp Ther; 2008 Jul; 326(1):218-29. PubMed ID: 18420600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo.
    Surowy CS; Neelands TR; Bianchi BR; McGaraughty S; El Kouhen R; Han P; Chu KL; McDonald HA; Vos M; Niforatos W; Bayburt EK; Gomtsyan A; Lee CH; Honore P; Sullivan JP; Jarvis MF; Faltynek CR
    J Pharmacol Exp Ther; 2008 Sep; 326(3):879-88. PubMed ID: 18515644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amelioration of neuropathic pain by novel transient receptor potential vanilloid 1 antagonist AS1928370 in rats without hyperthermic effect.
    Watabiki T; Kiso T; Kuramochi T; Yonezawa K; Tsuji N; Kohara A; Kakimoto S; Aoki T; Matsuoka N
    J Pharmacol Exp Ther; 2011 Mar; 336(3):743-50. PubMed ID: 21098091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats.
    Honore P; Wismer CT; Mikusa J; Zhu CZ; Zhong C; Gauvin DM; Gomtsyan A; El Kouhen R; Lee CH; Marsh K; Sullivan JP; Faltynek CR; Jarvis MF
    J Pharmacol Exp Ther; 2005 Jul; 314(1):410-21. PubMed ID: 15837818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eriodictyol: a flavonoid antagonist of the TRPV1 receptor with antioxidant activity.
    Rossato MF; Trevisan G; Walker CI; Klafke JZ; de Oliveira AP; Villarinho JG; Zanon RB; Royes LF; Athayde ML; Gomez MV; Ferreira J
    Biochem Pharmacol; 2011 Feb; 81(4):544-51. PubMed ID: 21087598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. in vivo characterization in rat models of inflammatory and neuropathic pain.
    Pomonis JD; Harrison JE; Mark L; Bristol DR; Valenzano KJ; Walker K
    J Pharmacol Exp Ther; 2003 Jul; 306(1):387-93. PubMed ID: 12721336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and biological characterization of 6-aryl-7-isopropylquinazolinones as novel TRPV1 antagonists that are effective in models of chronic pain.
    Culshaw AJ; Bevan S; Christiansen M; Copp P; Davis A; Davis C; Dyson A; Dziadulewicz EK; Edwards L; Eggelte H; Fox A; Gentry C; Groarke A; Hallett A; Hart TW; Hughes GA; Knights S; Kotsonis P; Lee W; Lyothier I; McBryde A; McIntyre P; Paloumbis G; Panesar M; Patel S; Seiler MP; Yaqoob M; Zimmermann K
    J Med Chem; 2006 Jan; 49(2):471-4. PubMed ID: 16420034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans.
    Chizh BA; O'Donnell MB; Napolitano A; Wang J; Brooke AC; Aylott MC; Bullman JN; Gray EJ; Lai RY; Williams PM; Appleby JM
    Pain; 2007 Nov; 132(1-2):132-41. PubMed ID: 17659837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and synthesis of 2,7-diamino-thiazolo[5,4-d]pyrimidine derivatives as TRPV1 antagonists.
    Lebsack AD; Branstetter BJ; Hack MD; Xiao W; Peterson ML; Nasser N; Maher MP; Ao H; Bhattacharya A; Kansagara M; Scott BP; Luo L; Rynberg R; Rizzolio M; Chaplan SR; Wickenden AD; Guy Breitenbucher J
    Bioorg Med Chem Lett; 2009 Jan; 19(1):40-6. PubMed ID: 19038548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.